Evidence map›Paper›PMID 26538066›Full record

ArticleBMC medical genomics2015

Gene-expression patterns in peripheral blood classify familial breast cancer susceptibility.

Stephen R Piccolo, Irene L Andrulis, Adam L Cohen, Thomas Conner, Philip J Moos, Avrum E Spira, Saundra S Buys, W Evan Johnson, Andrea H Bild

Open access · goldAbstract read
In one paragraph

Article in BMC medical genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Stephen R PiccoloDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA. stephen_piccolo@byu.edu.
Irene L AndrulisLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada. ANDRULIS@lunenfeld.ca.
Adam L CohenHuntsman Cancer Institute, Salt Lake City, UT, USA. adam.cohen@hci.utah.edu.
Thomas ConnerHuntsman Cancer Institute, Salt Lake City, UT, USA. tom.conner@hci.utah.edu.
Philip J MoosDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA. Philip.Moos@pharm.utah.edu.
Avrum E SpiraDivision of Computational Biomedicine, Boston University School of Medicine, Boston, MA, USA. aspira@bu.edu.
Saundra S BuysHuntsman Cancer Institute, Salt Lake City, UT, USA. saundra.buys@hci.utah.edu.
W Evan JohnsonDivision of Computational Biomedicine, Boston University School of Medicine, Boston, MA, USA. wej@bu.edu.
Andrea H BildDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA. andreab@genetics.utah.edu.
University of Utah · USHuntsman Cancer Institute · USBoston University · USLunenfeld-Tanenbaum Research Institute · CA

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
University of Utah Center for Clinical and Translational ScienceUL1TR001067 · NCATS · UNIVERSITY OF UTAH · PI DERE, WILLARD H., HESS, RACHEL · 2013 to 2017
$19.8M
UNIVERSITY OF UTAH CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCE-UL1: BPCAUL1RR025764 · NCRR · UNIVERSITY OF UTAH · PI MCCLAIN, DONALD A. · 2008 to 2011
$19.4M
Core-001U01CA164920 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Irene Andrulis, Sarah Violet Colonna · 2018 to 2026
$17.0M
Breast Cancer Family Registry CohortUM1CA164920 · NCI · CANCER PREVENTION INSTIT OF CALIFORNIA · PI ANDRULIS, IRENE, BUYS, SAUNDRA S · 2012 to 2017
$12.7M
MULTIDISCIPLINARY CANCER RESEARCH TRAINING PROGRAMT32CA093247 · NCI · UNIVERSITY OF UTAH · PI AYER, DONALD E · 2002 to 2011
$5.2M
Utah Breast Cancer Family RegistryU01CA069446 · NCI · UNIVERSITY OF UTAH · PI BUYS, SAUNDRA S · 1995 to 2010
$4.6M
Epigenetic changes and phenotype-specific therapeutic strategies in breast cancerR01GM085601 · NIGMS · UNIVERSITY OF UTAH · PI BILD, ANDREA HOPE, JEFFREY, STEFANIE S. · 2008 to 2011
$1.7M
Statistical Tools and Methods for Next-Generation Sequencing in EpigeneticsR01HG005692 · NHGRI · BRIGHAM YOUNG UNIVERSITY · PI JOHNSON, WILLIAM EVAN · 2010 to 2014
$1.7M
NCATS NIH HHS UL1 TR001067NCI NIH HHS 5T32CA093247NCI NIH HHS P30 CA042014NCI NIH HHS P30CA042014NCI NIH HHS T32 CA093247NCI NIH HHS U01 CA069446NCI NIH HHS U01 CA164920NCI NIH HHS U01CA69446NCI NIH HHS UM1 CA164920NCRR NIH HHS UL1 RR025764NCRR NIH HHS UL1RR025764NHGRI NIH HHS 1R01HG005692NHGRI NIH HHS R01 HG005692NIGMS NIH HHS R01 GM085601NIGMS NIH HHS R01GM085601
6 · The paper itself

Abstract

backgroundWomen with a family history of breast cancer face considerable uncertainty about whether to pursue standard screening, intensive screening, or prophylactic surgery. Accurate and individualized risk-estimation approaches may help these women make more informed decisions. Although highly penetrant genetic variants have been associated with familial breast cancer (FBC) risk, many individuals do not carry these variants, and many carriers never develop breast cancer. Common risk variants have a relatively modest effect on risk and show limited potential for predicting FBC development. As an alternative, we hypothesized that additional genomic data types, such as gene-expression levels, which can reflect genetic and epigenetic variation, could contribute to classifying a person's risk status. Specifically, we aimed to identify common patterns in gene-expression levels across individuals who develop FBC.

methodsWe profiled peripheral blood mononuclear cells from women with a family history of breast cancer (with or without a germline BRCA1/2 variant) and from controls. We used the support vector machines algorithm to differentiate between patients who developed FBC and those who did not. Our study used two independent datasets, a training set of 124 women from Utah (USA) and an external validation (test) set from Ontario (Canada) of 73 women (197 total). We controlled for expression variation associated with clinical, demographic, and treatment variables as well as lymphocyte markers.

resultsOur multigene biomarker provided accurate, individual-level estimates of FBC occurrence for the Utah cohort (AUC = 0.76 [0.67-84]) . Even at their lower confidence bounds, these accuracy estimates meet or exceed estimates from alternative approaches. Our Ontario cohort resulted in similarly high levels of accuracy (AUC = 0.73 [0.59-0.86]), thus providing external validation of our findings. Individuals deemed to have "high" risk by our model would have an estimated 2.4 times greater odds of developing familial breast cancer than individuals deemed to have "low" risk.

conclusionsTogether, these findings suggest that gene-expression levels in peripheral blood cells reflect genomic variation associated with breast cancer risk and that such data have potential to be used as a non-invasive biomarker for familial breast cancer risk.

Indexed as

TranscriptomeAdultBreast NeoplasmsCase-Control StudiesCohort StudiesComputational BiologyFemaleGenetic Predisposition to DiseaseHumansLeukocytes, MononuclearMiddle AgedMutationPedigreeSupport Vector Machine

Identifiers

PMID26538066
PMCPMC4634735
OpenAlexW2151968075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.